Biotron Limited

Biotron Limited (ASX:BIT) (OTCMKTS:BITRF) was pleased to recently announce that it has achieved another key milestone, with the final patient enrolled in an important Phase 2 clinical trial of BIT225 in patients co-infected with Hepatitis C virus (HCV) and HIV.

Asian Activities Report for September 30, 2011 includes: Neon Energy Limited (ASX:NEN) says today that the recently drilled Lombardi 19-27H development well in the North San Ardo oil field, onshore California, has been brought onstream; India Resources Limited (ASX:IRL) has signed a A$249M coal operations contract with Prism Cement Limited (BOM:500338) to develop and operate the first phase of Prism's Sial Ghoghri coal mine; Guildford Coal Limited (ASX:GUF) has upgraded its Exploration Targets at its Mongolian coal projects to 30Mt to 1.380Bt; Tissue Therapies Limited (ASX:TIS) will start the sales of VitroGro(R) for the treatment of chronic wounds in the UK and Europe during the second quarter of 2012; Biotron Limited (ASX:BIT) has commenced a human trial of its lead HIV drug candidate, BIT225; Circadian Technologies Limited (ASX:CIR) has submitted an investigational new drug application to the FDA to initiate clinical studies of VGX-100.